Browse the evidence

Lifestyle interventions (caloric deficit and exercise) remain the cornerstone of obesity care but are often insufficient for long-term maintenance without pharmacotherapy.

Start with a 500-750 kcal daily deficit and 150 minutes of moderate exercise per week. Aim for 5-10% weight loss in 6 months. If you struggle to maintain this, consider adding pharmacotherapy, as lifestyle changes alone are often insufficient for long-term maintenance.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.

Understand that GLP-1 therapy is likely a long-term commitment. If you stop taking the medication, you will likely regain most of the weight you lost. Plan for ongoing management rather than a fixed 'end date' for treatment.

Testosterone therapy (TTh) combined with GLP-1 receptor agonists (GLP-1RAs) and lifestyle modifications constitutes a comprehensive standard of care for obese men with functional hypogonadism, addressing metabolic, vascular, sexual, cognitive, and skeletal health.

For obese men with low testosterone, combining testosterone therapy with GLP-1RA medications (like semaglutide or liraglutide) and lifestyle changes (diet and exercise) is the most effective strategy. This approach not only boosts testosterone but also improves metabolic health, sexual function, and bone density, offering a comprehensive solution to obesity-related hormonal issues.

Patient preferences for GLP-1 receptor agonist outcomes vary substantially by demographic factors (age, sex, BMI), with younger individuals and women expressing significantly higher concern regarding cosmetic side effects like alopecia and severe gastrointestinal outcomes compared to older men.

If you are considering GLP-1 medication, your personal tolerance for side effects matters more than the average patient's experience. Younger women, in particular, may find hair loss or GI issues more distressing than older men. Discuss these specific fears with your doctor before starting, as they significantly impact whether you will stick with the treatment long enough to see benefits.

Dietary interventions alone are insufficient for long-term obesity management due to biological resistance mechanisms that promote weight regain, necessitating a multi-modal approach including physical activity, behavioral therapy, pharmacotherapy, or surgery.

Stop looking for a single 'magic' diet that cures obesity. Sustainable weight management requires a combination of safe nutrition, regular physical activity, and behavioral support. If lifestyle changes are insufficient, consult a doctor about pharmacotherapy or surgery. Focus on long-term health improvements (blood pressure, glucose) rather than just the number on the scale, and be aware that biological mechanisms will fight weight loss, so ongoing maintenance strategies are essential.

Primary prevention of obesity through population-level public health measures is more cost-effective and yields better results than treating established obesity.

Healthcare systems should prioritize policies that promote healthy eating and physical activity for the entire population, such as regulating advertising of unhealthy foods and building accessible recreational spaces. For individuals, focusing on maintaining a healthy weight from a young age is more effective and less costly than trying to treat obesity later in life.

Dual incretin agonists (e.g., Tirzepatide) reduce total body fat mass and adipocyte size more effectively than selective GLP-1 receptor agonists (e.g., Semaglutide, Dulaglutide) by modulating both GLP-1 and GIP receptors, leading to enhanced lipolysis and reduced visceral fat.

If you are considering a dual incretin agonist like Tirzepatide, be aware that it targets two hormonal pathways (GLP-1 and GIP) rather than just one. This dual action leads to a significantly greater reduction in total body fat and visceral fat compared to single-target GLP-1 drugs, offering a more potent option for weight management.

Higher baseline circulating leptin levels in patients correlate with greater weight loss efficacy when treated with tirzepatide.

If you have obesity and type 2 diabetes, your baseline leptin level may predict how much weight you will lose with tirzepatide. Higher leptin levels are associated with greater weight loss, suggesting that combination therapy with leptin might be particularly beneficial for those with higher baseline levels.

GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than bariatric surgery in some metrics, but surgery remains superior for long-term durability and metabolic improvement, making GLP-1RAs a viable non-surgical alternative for patients who cannot or will not undergo surgery.

If you have obesity and want significant weight loss without surgery, ask your doctor about GLP-1 receptor agonists like semaglutide (2.4 mg weekly). These drugs work by slowing digestion and signaling fullness to your brain. They can lead to about 15% body weight loss over 16 months, which is substantial. Be prepared for potential nausea or digestive issues, which often improve over time. This is a medical treatment, not a quick fix, and works best when combined with lifestyle changes.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces the prevalence of metabolic syndrome by improving its core components: glycemic control, body weight, lipid profiles, and blood pressure.

If you have metabolic syndrome (high blood pressure, high blood sugar, high cholesterol, and excess belly fat), talk to your doctor about tirzepatide. It is a once-weekly injection that helps lower blood sugar, reduce weight, improve cholesterol, and lower blood pressure. While it can cause temporary stomach issues, these often go away, and it may offer a more comprehensive solution than lifestyle changes alone.

GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss in patients with type 2 diabetes and obesity through mechanisms including enhanced glucose-dependent insulin secretion, suppressed glucagon release, delayed gastric emptying, and central appetite suppression.

GLP-1 receptor agonists are highly effective medications for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to increase insulin when needed, suppress glucagon, slow down digestion, and reduce appetite. This leads to significant weight loss and better blood sugar control with a lower risk of hypoglycemia compared to older diabetes drugs. Common side effects like nausea are usually temporary and can be managed by starting with a low dose and increasing it gradually. Both injectable and oral options exist, making them accessible for many patients.

Dual and triple receptor agonists (targeting GLP-1, GIP, and/or Glucagon) provide superior weight loss and glycemic control compared to selective GLP-1 receptor agonists alone.

Newer medications that target multiple hormones (GLP-1, GIP, and Glucagon) are more effective for weight loss and blood sugar control than older GLP-1 drugs alone. Drugs like tirzepatide and retatrutide have shown remarkable results, with some patients losing over 20% of their body weight. These are taken once a week and are considered a major advancement in treating obesity and diabetes.

In individuals with obesity and multiple long-term conditions (MLTCs), BMI reductions of ≥7% are associated with a lower risk of developing new obesity-related complications (ORCs) and reduced polypharmacy compared to stable BMI, whereas both significant weight loss and weight gain are associated with increased hazards for mental-health conditions, hospitalization, and mortality.

For people with obesity and multiple chronic conditions, losing weight (≥7%) can help prevent new diseases and reduce the number of medications. However, this population also faces higher risks of mental health issues, hospitalization, and mortality with both weight loss and gain compared to maintaining a stable weight. Treatment should be personalized, focusing on overall health outcomes rather than weight change alone.

Discontinuation of incretin analogues (semaglutide, tirzepatide) leads to significant weight regain, with patients recovering approximately two-thirds of lost weight within one year.

If you stop taking semaglutide or tirzepatide, you will likely regain about two-thirds of the weight you lost within a year. This is because the medication's appetite-suppressing effects wear off. To maintain your weight loss, you likely need to continue the medication long-term under medical supervision.

Bariatric surgery remains the most efficacious treatment for obesity, producing sustained weight loss of approximately 20% or higher and superior metabolic improvements compared to pharmacotherapy alone.

If you have severe obesity, bariatric surgery is currently the most effective medical intervention for achieving significant, sustained weight loss and reversing metabolic diseases like type 2 diabetes. While it is invasive, it is considered safe and offers better long-term outcomes than medication alone for many patients.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide can achieve weight loss comparable to sleeve gastrectomy in selected patients, but are limited by real-world factors like cost, tolerability, and adherence.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often achieving 15-20% body weight reduction. However, success depends on continuous use; stopping the medication often leads to weight regain. Managing side effects through gradual dosing and addressing cost/access are key to long-term success.

GLP-1 receptor agonists provide renal benefits, including reduced albuminuria and slower eGFR decline, in patients with type 2 diabetes and chronic kidney disease, independent of glycemic control.

If you have type 2 diabetes and chronic kidney disease, GLP-1 RAs like semaglutide can protect your kidneys by reducing albuminuria and slowing the decline of kidney function, even independent of their glucose-lowering effects. Discuss these benefits with your doctor, especially if you are already on other kidney-protective medications.

GLP-1 receptor agonists (semaglutide, tirzepatide, survodutide, retatrutide) promote resolution of metabolic dysfunction-associated steatohepatitis (MASH) and improve liver fibrosis in patients with MASLD/MASH.

If you have MASH or MASLD, GLP-1 RAs like semaglutide and tirzepatide can significantly improve liver health, resolving MASH in many patients and improving fibrosis. These benefits are in addition to their weight loss and cardiovascular benefits. Discuss these options with your liver specialist or primary care provider.

For older adults (≥65 years) with obesity, weight reduction is recommended only after careful consideration of risks/benefits and patient priorities, whereas overweight older adults should maintain stable body weight to avoid sarcopenia and functional decline.

If you are over 65 and obese, focus on a small calorie cut (500 kcal less than usual) combined with strength training and high protein intake (1-1.5g per kg of body weight). If you are merely overweight, do not try to lose weight; focus on maintaining your current weight and muscle mass to prevent frailty.

Semaglutide (1.0 mg once weekly) significantly improves physical quality of life (SF-36v2 PCS) in patients with schizophrenia and obesity, with the effect exceeding the minimally important difference, although this improvement is not statistically mediated by weight loss.

If you have schizophrenia and are overweight, semaglutide (1.0 mg weekly) can significantly improve your physical quality of life, such as mobility and physical functioning. This benefit is clinically meaningful and exceeds the threshold for what patients consider important. However, do not expect this medication to directly reduce psychiatric symptoms like hallucinations or negative symptoms, nor does it necessarily improve mental well-being (MCS). The improvement in physical QoL is not solely due to weight loss, suggesting the drug has other beneficial effects. Adherence to the weekly injection is key to achieving these physical health benefits.

Orforglipron reduces systolic blood pressure and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency (low heterogeneity) across doses, suggesting a mechanism independent of weight loss alone.

For cardiovascular health, you may not need the highest dose of Orforglipron. Lower doses (12-24 mg) are sufficient to significantly improve blood pressure and cholesterol levels, while higher doses are needed for maximum weight loss. This allows for a personalized dosing strategy.

Combination therapy of semaglutide and cagrilintide (CagriSema) produces weight loss comparable to multi-receptor agonists by targeting complementary metabolic pathways.

Taking semaglutide and cagrilintide together (CagriSema) is a highly effective strategy for weight loss, performing similarly to newer triple-agonist drugs. It involves two weekly injections. Like other drugs in this class, you may experience gastrointestinal side effects initially, which usually improve over time.

Dual GIP/GLP-1 receptor agonists (tirzepatide) demonstrate enhanced efficacy compared to single GLP-1 agonists, likely due to synergistic modulation of GIP and GLP-1 pathways.

Tirzepatide is a dual-acting drug (GIP and GLP-1) that is more effective than single-acting GLP-1 drugs like semaglutide. It is taken once weekly. You will likely experience gastrointestinal side effects initially, which usually improve over time.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce body weight and improve metabolic parameters by modulating central appetite pathways and delaying gastric emptying.

GLP-1 drugs like semaglutide and liraglutide help you lose weight by reducing appetite and slowing digestion. They are taken daily or weekly. Gastrointestinal side effects are common initially but usually improve.